Gail Dutton

ARTICLES BY GAIL DUTTON

• “New Science” Alleviates Economic Constraints

  According to a new report by Accenture, “New Science” – molecular medicine plus new healthcare technologies – can ease the compression and position biopharma companies for exceptional growth.

• Laying The Foundation For One-Time Therapeutic Reimbursement

  Enzyvant expects its BLA for a tissue-based regenerative therapy to be reviewed and potentially approved in 2019, so solving the reimbursement issue is urgent for both the company and for patients.

• Foreign Investors Trigger ‘Critical Technology’ Review for Biotech

  New, cross-border investments trigger federal scrutiny via CFIUS when emerging biotech technology is involved.

• 2019: The Year Of Value-based Healthcare

  The value of China’s biotechs fell some 30 percent since the trade war began, and VC funding, while strong, slipped before that. Interest in China, however, remains strong.

• Is China’s Golden Era Ending?

  The value of China’s biotechs fell some 30 percent since the trade war began, and VC funding, while strong, slipped before that. Interest in China, however, remains strong.

• Serendipity: When Funders Found A Company

  Foghorn Therapeutics is managing to sidestep some of the growing pains common to early companies, thanks to its genesis as a VC-founded company.

• Mitigating Risks In Countries With Poor IP Protection

  IP theft seems inevitable when pharma companies enter regions with weak IP. That risk is reduced, however, when companies spread their activities throughout the region rather than centralizing them in one country.

• Why A Spin-off Is A Win-Win For Big Pharma And Startups

  When Viela Bio spun out of MedImmune last spring, it started with some assets well into development. Now it’s focusing on speed and continuity as it advances those assets through the clinic.

• Breaking Free Of Data Silos Demands A Comprehensive Strategy

  With a hypercompetitive landscape and growing demands for real world data, companies need a comprehensive, cross-silo, data strategy to uncover unobvious insights and develop new data streams.

• Pharma Needs A New Business Model

  Pharmas have a decision to make: Are they drug developers, or are they healthcare companies? Whatever the answer, the proliferation of innovative digital solutions is triggering the need for new business models tailored to what companies want to become, rather than what they’ve always been.